cilostazol has been researched along with quercetin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hong, KW; Kim, CD; Kim, HY; Park, HJ; Park, SY; Shin, HK | 1 |
| Hayashi, SM; Hippo, Y; Kangawa, Y; Kihara, T; Maruyama, K; Nakamura, M; Ochiai, M; Okamoto, M; Shibutani, M; Yoshida, T | 1 |
| Abe, H; Hayashi, SM; Kangawa, Y; Kihara, T; Miyashita, T; Nakamura, M; Seto, Y; Shibutani, M; Yoshida, T | 1 |
| Ihara, M; Inoue, T; Saito, S; Satoh-Asahara, N; Tanaka, M | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 review(s) available for cilostazol and quercetin
| Article | Year |
|---|---|
Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Biomarkers; Brain; Cerebral Amyloid Angiopathy; Cilostazol; Disease Models, Animal; Humans; Membrane Glycoproteins; Mice; Neuroprotective Agents; Oxidative Stress; Protein Aggregation, Pathological; Quercetin; Receptors, Immunologic | 2020 |
6 other study(ies) available for cilostazol and quercetin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cells, Cultured; Cilostazol; Down-Regulation; Drug Synergism; Janus Kinase 2; Mice; Neuroprotection; Neuroprotective Agents; NF-kappa B; Phosphorylation; Quercetin; Signal Transduction; STAT3 Transcription Factor; Tetrazoles | 2016 |
Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation.
Topics: Animals; Azoxymethane; Carcinogens; Cell Proliferation; Cilostazol; Colitis; Colonic Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Immunohistochemistry; Inflammation; Mice; Mice, Inbred BALB C; Organ Size; Quercetin; Tetrazoles; Vasodilator Agents | 2017 |
Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cilostazol; Colitis; Dextran Sulfate; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Oligonucleotide Array Sequence Analysis; Phosphodiesterase 3 Inhibitors; Quercetin; Tetrazoles; Thioctic Acid | 2017 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |